-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Non-Small Cell Lung Cancer Drug Details: LP-184...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Melanoma Drug Details: LP-184 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Central Nervous System (CNS) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Central Nervous System (CNS) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Central Nervous System (CNS) Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in High-Grade Glioma Drug Details: LP-184 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LP-184...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-184 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-184 in Triple-Negative Breast Cancer (TNBC) Drug Details: LP-184...
-
Product Insights
Pediatric Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Pediatric Cancer - Drugs In Development, 2023’, provides an overview of the Pediatric Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pediatric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Teratoid Rhabdoid Tumor - Drugs In Development, 2023’, provides an overview of the Atypical Teratoid Rhabdoid Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pediatric Diffuse Intrinsic Pontine Glioma - Drugs In Development, 2023’, provides an overview of the Pediatric Diffuse Intrinsic Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pediatric Diffuse Intrinsic Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...